论文信息 - Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders.

Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders.

The synthesis and evaluation of inhibitors of activated protein C (aPC) are reported. This serine protease is partly responsible for the degradation of factor VIIIa, involved in the regulation of bleeding in hemophilia A. Benzamidine-containing derivatives were found to be potent aPC inhibitors, some of them showing selectivity against the procoagulant protease thrombin. Moreover, compound 1 significantly restored the generation of thrombin in hemophiliac plasma.

[1] M. Kraus. The Anticoagulant Potential of the Protein C System in Hereditary and Acquired Thrombophilia: Pathomechanisms and New Tools for Assessing its Clinical Relevance , 1998, Seminars in thrombosis and hemostasis.

[2] T. Verbeuren,et al. Large Scale Preparation of Protected 4-Aminomethylbenzamidine. Application to the Synthesis of the Thrombin Inhibitor, Melagatran. , 1999 .

[3] A Abrahamsson,et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.

[4] H. Nar,et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. , 2002, Journal of medicinal chemistry.

[5] S. Béguin,et al. The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability , 2002, Pathophysiology of Haemostasis and Thrombosis.

[6] C. Hauser,et al. Hemophilia A--from basic science to clinical practice. , 2002, Seminars in thrombosis and hemostasis.

[7] H. Coenraad Hemker,et al. Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[8] P. Bishop,et al. Recombinant biologics for treatment of bleeding disorders , 2004, Nature Reviews Drug Discovery.